Sage Journals: Discover world-class research

Abstract

Background:

The optimal timing of treatment starts for achieving the best control on the long-term disability accumulation in multiple sclerosis (MS) is still to be defined.

Objective:

The aim of this study was to estimate the optimal time to start disease-modifying therapies (DMTs) to prevent the long-term disability accumulation in MS, using a pooled dataset from the Big Multiple Sclerosis Data (BMSD) network.

Methods:

Multivariable Cox regression models adjusted for the time to first treatment start from disease onset (in quintiles) were used. To mitigate the impact of potential biases, a set of pairwise propensity score (PS)-matched analyses were performed. The first quintile, including patients treated within 1.2 years from onset, was used as reference.

Results:

A cohort of 11,871 patients (median follow-up after treatment start: 13.2 years) was analyzed. A 3- and 12-month confirmed disability worsening event and irreversible Expanded Disability Status Scale (EDSS) 4.0 and 6.0 scores were reached by 7062 (59.5%), 4138 (34.9%), 3209 (31.1%), and 1909 (16.5%) patients, respectively. The risk of reaching all the disability outcomes was significantly lower (p < 0.0004) for the first quintile patients’ group.

Conclusion:

Real-world data from the BMSD demonstrate that DMTs should be commenced within 1.2 years from the disease onset to reduce the risk of disability accumulation over the long term.

Keywords

Multiple sclerosis big data early treatment EDSS

Get full access to this article

View all access options for this article.

References

Rotstein

Montalban

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 2019; 15(5): 287–300.

Trojano

Pellegrini

Fuiani

, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300–306.

Tedeholm

Lycke

Skoog

, et al. Time to secondary progression in patients with multiple sclerosis treated with first generation immunomodulating drugs. Mult Scler 2013; 19: 765–774.

Bergamaschi Quaglini

Tavazzi

Amato

, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 2016; 22(13): 1732–1740.

Brown

JWL

Coles

Horakova

, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321(2): 175–187.

Palace

Duddy

Lawton

, et al. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: Final 10-year results from the UK multiple sclerosis risk-sharing scheme. J Neurol Neurosurg Psychiatry 2019; 90(3): 251–260.

Merkel

Butzkueven

Traboulsee

, et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmun Rev 2017; 16(6): 658–665.

Jacobs

Beck

Simon

, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904.

Comi

Filippi

Barkhof

, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357: 1576–1582.

10.

Comi

Martinelli

Rodegher

, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503–1511.

11.

Comi

Martinelli

Rodegher

, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013; 19(8): 1074–1083.

12.

Kappos

Traboulsee

Constantinescu

, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 94417–94453.

13.

Kappos

Polman

Freedman

, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249.

14.

Kappos

Edan

Freedman

, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 2016; 87: 978–987.

15.

Kinkel

Kollman

O’Connor

, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678–684.

16.

Kinkel

Dontchev

Kollman

, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: A 10-year follow-up of the controlled high-risk avonex multiple sclerosis prevention study in ongoing neurological surveillance. Arch Neurol 2012; 69(2): 183–190.

17.

Miller

Wolinsky

Kappos

, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13(10): 977–986.

18.

Tintore

Rovira

Rio

, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(Pt. 7): 1863–1874.

19.

Iaffaldano

Simone

Lucisano

, et al. Prognostic indicators in pediatric clinically isolated syndrome. Ann Neurol 2017; 81: 729–739.

20.

Trojano

Pellegrini

Paolicelli

, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009; 66(4): 513–520.

21.

Jokubaitis

Spelman

Kalincik

, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol 2016; 80(1): 89–100.

22.

Kavaliunas

Manouchehrinia

Stawiarz

, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 2017; 23(9): 1233–1240.

23.

Landfeldt

Castelo-Branco

Svedbom

, et al. The long-term impact of early treatment of multiple sclerosis on the risk of disability pension. J Neurol 2018; 265(3): 701–707.

24.

Goodin

Reder

Ebers

, et al. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012; 78: 131517–131522.

25.

Chalmer

Baggesen

Nørgaard

, et al. Early versus later treatment start in multiple sclerosis: A register-based cohort study. Neurol 2018; 25: 1262-e110.

26.

Kingwell

Leray

Zhu

, et al. Multiple sclerosis: Effect of beta interferon treatment on survival. Brain 2019; 142(5): 1324–1333.

27.

Magyari

Koch-Henriksen

Sorensen

PS.

The Danish multiple sclerosis treatment register. Clin Epidemiol 2016; 8: 549–552.

28.

Trojano

Bergamaschi

Amato

, et al. The Italian multiple sclerosis register. Neurol Sci 2019; 40(4): 155–167.

29.

Hillert

Stawiarz

The Swedish MS registry – clinical support tool and scientific resource. Acta Neurol Scand 2015; 132(199): 11–19.

30.

Vukusic

Casey

Rollot

, et al. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. Mult Scler 2018; 26: 1352458518815602.

31.

Butzkueven

Chapman

Cristiano

, et al. MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006; 12(6): 769–774.

32.

Austin

Grootendorst

Anderson

GM.

A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med 2007; 26(4): 734–753.

33.

Rae-Grant

Day

Marrie

, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018; 90(17): 777–788.

34.

Montalban

Gold

Thompson

, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24(2): 96–120.

35.

Ribbons

McElduff

Boz

, et al. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PLoS ONE 2015; 10: e0122686.

36.

Scalfari

Neuhaus

Degenhardt

, et al. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133(Pt. 7): 1914–1929.

37.

Stewart

Spelman

Havrdova

, et al. Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler 2017; 23(2): 266–276.

38.

Scalfari

Neuhaus

Daumer

, et al. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77(13): 1246–1252.

39.

Trojano

Tintore

Montalban

, et al. Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nat Rev Neurol 2017; 13(2): 105–118.

40.

Harding

Williams

Willis

, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019; 76: 536–541.

41.

Merkel

Brown

JWL

, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol 2020; 19(4): 307–316.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB

0.02 MB

0.11 MB

0.09 MB

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material